摘要
目的:系统评价脑心通胶囊治疗冠心病心绞痛的临床疗效和安全性,为临床用药提供循证参考依据.方法:检索中国期刊全文数据库、中文科技期刊全文数据库、万方数据库、PubMed、the Cochrane Library、EMBase及Web of Science等数据库,检索时限为建库至2018年6月,收集脑心通胶囊治疗冠心病心绞痛的随机对照试验(对照组患者采用化学药常规治疗,研究组患者在常规治疗基础上加用脑心通胶囊),采用RevMan 5.3软件进行文献荟萃分析(Meta分析).结果:共纳入44篇文献,涉及5130例患者.Meta分析结果显示,研究组患者的心电图改善情况(RR=1.34,95%CI=1.26~1.42,P<0.00001)、心绞痛症状改善情况(RR=1.24,95%CI=1.19~1.29,P<0.00001)及临床疗效(RR=1.20,95%CI=1.15~1.25,P<0.00001)均明显优于对照组,差异均有统计学意义;研究组患者不良反应发生率明显高于对照组,差异有统计学意义(RR=3.62,95%CI=2.39~5.47,P<0.00001).结论:脑心通胶囊用于冠心病心绞痛的治疗,能显著改善心电图疗效,缓解心绞痛症状,提高临床疗效,但安全性较单独使用常规治疗略低.
OBJECTIVE:To systematically evaluate the clinical efficacy and safety of Naoxintong capsules in the treatment of angina pectoris,so as to provide evidence-based reference for clinical drug use.METHODS:CNKI,VIP database,Wanfang database,PubMed,the Cochrane Library,EMBase and Web of Science were retrieved to collect the randomized controlled trials of Naoxintong capsules in the treatment of angina pectoris(the control group was treated conventionally with chemical drugs,while the study group received Naoxintong capsules on the basis of the conventional treatment).The retrieval time was from the establishment of the database to Jun.2018.Literature Meta-analysis was performed by using RevMan 5.3 software.RESULTS:A total of 44 literature were collected,including 5130 patients.The results of Meta-analysis showed that the improvement of ECG(RR=1.34,95%CI=1.26-1.42,P<0.00001),the improvement of angina symptoms(RR=1.24,95%CI=1.19-1.29,P<0.00001)and the clinical efficacy(RR=1.20,95%CI=1.15-1.25,P<0.00001)in the study group were significantly better than those in the control group,with statistically significant differences.The incidence of adverse reactions in the study group was significantly higher than that in the control group,with statistically significant difference(RR=3.62,95%CI=2.39-5.47,P<0.00001).CONCLUSIONS:Naoxintong capsules in the treatment of angina pectoris can significantly improve the efficacy of electrocardiogram,alleviate the symptoms of angina pectoris,improve the clinical efficacy,but with slightly lower safety compared to the conventional treatment alone.
作者
李春晓
陈玉欢
李学林
唐进法
张明亮
徐涛
张辉
凌霄
LI Chunxiao;CHEN Yuhuan;LI Xuelin;TANG Jinfa;ZHANG Mingliang;XU Tao;ZHANG Hui;LING Xiao(Dept.of Pharmacy,the First Affiliated Hospital of Henan University of Chinese Medicine,Henan Zhengzhou 450000,China;Henan Province Engineering Laboratory for Clinical Evaluation Technology of Traditional Chinese Medicine,Henan Zhengzhou 450000,China;Henan Province Collaborative Innovation Center for Diagnosis and Treatment of Respiratory Diseases and Research and Development of New Drugs,Henan Zhengzhou 450000,China;College of Pharmacy,Henan University of Chinese Medicine,Henan Zhengzhou 450000,China)
出处
《中国医院用药评价与分析》
2019年第12期1494-1499,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
重大新药创制“符合中药特点的安全用药风险评控关键技术”子课题（No.2015ZX09501004-001-007）
河南省中医管理局河南省中医药科学研究专项课题（No.2016ZY1006）
